Navigation Links
Bronchitol Cystic Fibrosis Dose Trial Results Positive
Date:8/11/2008

Bronchitol Demonstrates Dose-Related Improvements in Lung Function of

Cystic Fibrosis Patients

SYDNEY, Australia, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Speciality pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results from its Phase II trial, DPM-CF-202, in subjects with cystic fibrosis.

The trial achieved its primary end point of demonstrating a dose dependent improvement in lung function as measured by FVC (forced vital capacity) and FEV1 (the amount of air that can be forcibly exhaled in 1 second). At the end of the two-week Bronchitol treatment periods, changes in lung function were as follows:

-- 400 mg treatment group: FEV1 increased by 8.6%

(139 mls, p=0.0006 vs 40 mg)

-- 240 mg treatment group: FEV1 increased by 4.6% (87 mls)

-- 120 mg treatment group: FEV1 increased by 3.7% (42 mls)

-- 40 mg treatment group: FEV1 decreased by -1.6% (-33 mls)

FVC changed by +7.9% on 400 mg (p=0.0004 vs 40 mg), +3.9% on 240 mg, +1.5% on 120 mg and -0.6% on 40 mg.

Pharmaxis Chief Executive Officer Alan Robertson said, "The excellent result from this trial reaffirms that the 400 mg Bronchitol dose being used in the Phase 3 trials is optimal for its clinical effectiveness. We look forward to the results from the ongoing Phase 3 studies and to bringing Bronchitol to the market as rapidly as possible."

The study was an open, randomised comparison of 400mg, 240 mg, 120 mg and 40 mg of Bronchitol in 48 patients with cystic fibrosis at 12 centres across Canada and Argentina. Bronchitol was administered twice a day for 14 days in a crossover design.

Secondary endpoints of the study included other spirometry and quality of life measures. These measures also showed a positive effect for 400 mg Bronchitol on MMEF (maximum mid expiratory flow) and the respiratory domain of the cystic fibrosis quality of life questionnaire (CFQR).

Add
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Promising Cystic Fibrosis Compound on Track for Development
5. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... WASHINGTON , July 22, 2014  Edwards Lifesciences ... in the science of heart valves and hemodynamic monitoring, ... Mussallem today served as an expert panelist at ... Committee,s Subcommittee on Health to discuss medical device innovation ... Barriers to Ongoing Evidence Development and Communication." ...
(Date:7/22/2014)...  Decision Resources Group finds that the market for interventional ... remain relatively stagnant at a value of around $80 million ... intervention (PCI) volumes are growing faster in Canada ... the United States and Europe ... increase in penetration of PCI procedures relative to coronary artery ...
(Date:7/22/2014)... -- The number of people overdosing from opioid prescription ... percent of the workforce has misused prescription painkillers, according ... making opioid use a serious threat to employee safety. ... correct dosage with a valid prescription, subtle impairment may ... Safety Council released a guide for employers, ...
Breaking Medicine Technology:Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Corporation (Nasdaq: DNDN ) today reported results for ... quarter ended September 30, 2010 was $20.2 million compared to ... the nine months ended September 30, 2010 was $23.1 million ... 2009.   Revenue from sales of PROVENGE® (sipuleucel-T) ...
... EMERYVILLE, Calif., Nov. 3, 2010 Onyx Pharmaceuticals, ... results for the third quarter 2010. Onyx reported non-GAAP net ... the third quarter 2010 compared to non-GAAP net income of ... period in 2009. Non-GAAP net income excludes, among other items, ...
Cached Medicine Technology:Dendreon Reports Third Quarter 2010 Financial Results 2Dendreon Reports Third Quarter 2010 Financial Results 3Dendreon Reports Third Quarter 2010 Financial Results 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 2Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 3Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 5Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 6Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 7Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 8Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 9Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 10
(Date:7/23/2014)... FCCI Insurance Group has been again recognized ... Association for helping employees eat better and move more. ... in 2013, 2011, and 2010, and as a Gold-Level ... and wellness an important priority. We’re committed to providing ... top of their game, and we are honored to ...
(Date:7/23/2014)... Princeview Dental ( http://www.PrinceviewDental.com ), one ... of having a complete oral exam. , “Oral exams ... oral health care, as there are so many benefits ... founder of Princeview Dental. “Dentists are trained to detect ... Just by observing the inside of the mouth, we ...
(Date:7/23/2014)... Washington, DC (PRWEB) July 23, 2014 ... prompting some state-run insurance exchanges to come up ... identify some of the myriad ways to accomplish ... Information Services’s Inside Health Insurance Exchanges (HEX). , ... that high” for state-run exchanges, Christopher Condeluci, an ...
(Date:7/23/2014)... 2014 QueenBeeTickets.com is reducing the prices of ... for rock music fans who are still in the process ... the site, they can use promo code “DISCOUNT” to get ... to view the inventory of discounted tickets at QueenBeeTickets.com. , ... September and October, with The Eagles concert tickets literally disappearing ...
(Date:7/23/2014)... 23, 2014 Temecula Valley Southern ... Valley Southern California Wine Country artisan food and ... two nights genuinely nourishing. Savor like locals at ... and Vindemia wineries; EAT Marketplace, Palumbo’s Ristorante, Robin’s ... Olive Oil,” announced Kimberly Adams, president and CEO, ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 3Health News:Princeview Dental, One of Etobicoke’s Trusted Dental Clinics, Addresses the Need to Have Complete Oral Exams 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:History of The Eagles Tour Tickets: QueenBeeTickets.com Reduces Prices on Remaining Inventory of Concert Tickets for 2014 Shows 2Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 2Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 3Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 4
... Subsidiary Continues its Strong Sales Presence in the ... Inc. ("Global Med" or the "Company") (OTC Bulletin ... company, today announced that its Inlog subsidiary has ... Software (Marketed as "Labo Serveur" in France) to ...
... cancers may be preventable, adopting a healthy lifestyle is more important than ... lifestyles than during busier times of the year. Texas Oncology suggests four ... out. , ... Dallas, Texas (PRWEB) May 27, 2009 -- With the ...
... Precyse Solutions, a leading provider of clinical documentation ... a two-year consulting and training agreement with IASIS ... includes peer-to-peer training regarding quality clinical documentation for ... its ability to utilize physician trainers to conduct ...
... N.J., May 27 Nuvilex, Inc. (OTC Bulletin ... today announces Jayhur Enterprises will distribute Infinitink (the ... removal) in Australia and New Zealand. The distribution ... exclusive contract to market, promote, market, distribute and ...
... side effect that could hamper immigration checks , , WEDNESDAY, ... drug capecitabine can cause people to lose their fingerprints, ... enter the United States, an oncologist warns. , Dr. ... the National Cancer Centre in Singapore, said he now ...
... Electronic Medical Record/Practice Management Software Company Aimed at ... TechnologyBLOOMFIELD HILLS, Mich., May 27 gloStream, a ... Microsoft Office embedded electronic medical record ("EMR") and ... has closed on a $7.5 million series B ...
Cached Medicine News:Health News:Global Med Technologies(R), Inc. Licenses and Deploys its EdgeLab Laboratory Software at Eugene Andre Hospital in Lyon, France 2Health News:Global Med Technologies(R), Inc. Licenses and Deploys its EdgeLab Laboratory Software at Eugene Andre Hospital in Lyon, France 3Health News:Global Med Technologies(R), Inc. Licenses and Deploys its EdgeLab Laboratory Software at Eugene Andre Hospital in Lyon, France 4Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 2Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 3Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 4Health News:Fighting Preventable Cancers: Texas Oncology Encourages a Healthy Summer Lifestyle 5Health News:IASIS Healthcare and Precyse Solutions Sign Two-Year Consulting Agreement 2Health News:IASIS Healthcare and Precyse Solutions Sign Two-Year Consulting Agreement 3Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 3Health News:Fingerprints May Vanish With Cancer Drug 2Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 2Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 3Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 4
... Merlin is a superior full-color, auto-focus, ... vision user in mind, Merlin enables the ... black and white, high contrast positive or ... video magnifier, this optional feature enables the ...
... purpose incubators designed to provide ... uniformity required for the most ... microprocessor controlled incubators feature push-button ... digital display, and built-in over-temperature ...
... Precision Economy Incubators available in five different ... of 1.4 cu. Ft. (39 liters), 2.5 ... ft. (129 liters. Equally important, Precision Economy ... excellent temperature sensitivity, stability, and uniformity. As ...
Aspheric diagnostic lens. 90D...
Medicine Products: